TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05250570

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Distress Tolerance - Benzodiazepine Discontinuation (DT-BD)
Description: This psychosocial treatment intervention uses a combination of interoceptive exposure therapy and elements of acceptance and commitment therapy (ACT) to assist individuals in tolerating benzodiazepine withdrawal symptoms and teaching skills to prevent relapse to benzodiazepine use. It will also provide psychoeducation about benzodiazepine use in OAT. Both intervention and control arms will receive identical benzodiazepine discontinuation taper protocols.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Relaxation Therapy
Description: The relaxation therapy control condition involves psychoeducation about benzodiazepine use in OAT and progressive muscle-relaxation training. Both intervention and control arms will receive identical benzodiazepine discontinuation taper protocols.
Study: NCT05197608

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: System Navigator
Description: Participants will be connected to a System Navigator, who is a trained staff embedded within their primary health clinic to support and help navigate biological, psychological and social needs in proactively identified vulnerable patients.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Tailored list of resources
Description: Control group will be provided a tailored list of resources
Study: NCT05053022

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Skinpen Precision System
Description: Subjects will receive a total of 8-12 treatments with the Skinpen Precision system targeting their Vitiligo lesions.
Study: NCT05175391

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Meat based protein with added spice; Plant based protein with added spice
Description: Either meat or plant based protein entrees will have herbs and spices added (in addition to salt and pepper in the base recipe) to intensify the flavor profile in order to see if protein consumption is affected.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Meat based protein with added spice; Plant based protein with added spice
Description: Either meat or plant based protein entrees will have herbs and spices added (in addition to salt and pepper in the base recipe) to intensify the flavor profile in order to see if protein consumption is affected.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Meat based protein with added spice; Plant based protein with added spice
Description: Either meat or plant based protein entrees will have herbs and spices added (in addition to salt and pepper in the base recipe) to intensify the flavor profile in order to see if protein consumption is affected.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Meat based protein with added spice; Plant based protein with added spice
Description: Either meat or plant based protein entrees will have herbs and spices added (in addition to salt and pepper in the base recipe) to intensify the flavor profile in order to see if protein consumption is affected.
Study: NCT02067260

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: X5 HairLaser
Description: Treatment consists of three, 10-15 minute, at-home treatments per week (on nonconcurrent days) for 26 weeks.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: X5 Hair Laser Sham Device
Description: Treatment consists of three, 10-15 minute, at-home treatments per week (on nonconcurrent days) for 26 weeks.
Study: NCT06132880

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Human Urinary Kallidinogenase
Description: Intravenous injections of urinary kallidinogenase (0.15 peptide nucleic acids (PNA) in 0.9% NaCl) intravenous drip QD for 10 days.

Intervention type: OTHER
Group type: OTHER
Intervention: Clinical Routine Treatment
Description: Conventional therapy of acute ischemic stroke after based on Chinese guidelines

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clinical Routine Treatment
Description: Conventional therapy of acute ischemic stroke after based on Chinese guidelines
Study: NCT05118009

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: AI-enabled ECG-based Screening Tool
Description: Primary care clinicians in the intervention group had access to the report, which displayed whether the AI-ECG result was positive or negative.The system will send a message to corresponding physicians if positive finding.
Study: NCT06522698

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Smart Pill Bottle
Description: Patients in the intervention group will have their opioid medication consumption monitored through a smart pill bottle that records medication usage and streamlines the data into an online platform accessible by the medical staff. This group will also fill out surveys delivered through the smart pill bottle's online platform.
Study: NCT05804422

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Probiotic lysate (postbiotic and metabiotc)
Description: Each capsule contains 100 mg of cell lysate and DNA fragments of the probiotic strain L. rhamnosus DV - NRRLB-68023 in powder

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT05908721

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CM310
Description: IL-4Rα monoclonal antibody
Study: NCT05870046

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Power training in women older than 65 years with pre-sarcopenia
Description: resistance training based on muscle power training, perform the exercises at high speed.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Multimodal and nonspecific exercises in women older than 65 years with pre-sarcopenia
Description: different exercise modalities are integrated: Aerobic, mobility, strength, balance and coordination exercises.
Study: NCT04733287

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High Intensity Interval Training of the Knee Extensors
Description: Subjects will perform intense, single leg knee extension exercise 3 times a week for 6 weeks. Specifically, subjects will be seated in a custom knee extension ergometer and perform single leg, dynamic knee extension (similar to single leg cycling) as they perform the exercise. After a 6 minute warm-up at \~20% of that leg's maximum aerobic power (determined during a graded exercise test of single leg knee extension), subjects will perform 4 bouts of 4 minutes at \~80% of maximum aerobic power. Recovery of 4 minutes at \~40% will occur between each bout of exercise. A cool down will be provided at the end of exercise. In total, subjects will perform 40 minutes of single leg knee extension exercise, 3 times a week for 6 weeks.~Maximum aerobic power (determined by a graded exercise test) will be determined again at 3 weeks to appropriately adjust the training intensity.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Muscle Heat Therapy
Description: Subjects will receive muscle heat therapy on the knee extensor muscles (short-wave diathermy) for 120 minutes for each visit. Specifically, subjects will lie supine while short-wave diathermy units (Megapulse II) will be placed on the quadriceps femoris and turned on to 800 pulses per second with a pulse duration of 400 microseconds. Our previous research (e.g. Hafen et al 2018- Repeated exposure to heat stress...) has indicated that this treatment raises muscle temperature to \~39C, a similar temperature induced by exercise.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Muscle Disuse
Description: Subjects will undergo 2 weeks of limb immobilization (a model of muscle disuse). Specifically, a knee brace will be placed on one of the subjects' legs and bent to a flexion of 60 degrees to prevent the foot from touching the ground while standing. Subjects will given a pair of crutches and asked to ambulate on crutches for 2 weeks, avoiding bearing any weight with the immobilized leg.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Heat Therapy
Description: Specifically, subjects randomly assigned to the sham group will receive the same treatment as the heat group (same number of visits and set up with the heating units applied to leg for 2 hours each visit) except, unbeknownst to either group, the heating units will never be turned on for the sham group.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Heat Therapy
Description: Specifically, subjects randomly assigned to the sham group will receive the same treatment as the heat group (same number of visits and set up with the heating units applied to leg for 2 hours each visit) except, unbeknownst to either group, the heating units will never be turned on for the sham group.
Study: NCT06270602

Intervention type: OTHER
Intervention: Data collection (retrospective)
Description: Collection of patient data entered in the ROC platform from the beginning activation of the platform (November 2018) until the date on which the study is approved by the local ethics committee
Study: NCT04889183

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide
Description: Patients will be treated for 24 weeks with semaglutide 3.0 mlg/ml s.c. once weekly. The starting dose of semaglutide will be 0.24 mg per week subcutaneous injection with increasing doses at 4, 8, 12, and 16 weeks to 0.5, 1,0, 1.7 and 2.4 mg.
Study: NCT06270602

Intervention type: OTHER
Intervention: Data collection (prospective)
Description: Collection of patient data entered in the ROC platform from the date in which the study is approved by the local ethical committee
Study: NCT04889183

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients will receive a matching placebo sc. once weekly during the treatment period of 24 weeks.
Study: NCT06584838

Intervention type: PROCEDURE
Intervention: ACL reconstruction
Description: Patients that underwent ACL reconstruction using either allograft or autograft tendons, at least 2 years of follow-up, gender male and female, no comorbidities
Study: NCT04716348

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: muscle energy technique
Description: muscle energy technique for suboccipital muscles

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: muscle energy technique
Description: muscle energy technique for suboccipital muscles
Study: NCT04155866

Intervention type: OTHER
Intervention: Measurement of muscle activation.
Description: Measurement of lower-limb muscle activation during walking for healthy participants.

Intervention type: OTHER
Intervention: Measurement of muscle activation.
Description: Measurement of lower-limb muscle activation during walking for healthy participants.
Study: NCT06308510

Intervention type: OTHER
Intervention: collection additional peritoneal lavage fluid
Description: collection additional peritoneal lavage fluid

Intervention type: OTHER
Intervention: collection additional peritoneal lavage fluid
Description: collection additional peritoneal lavage fluid
Study: NCT04853680

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Anti-adhesion barrier (Collarbarrier)
Description: Collagen derived anti-adhesion barrier
Study: NCT05686005

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral tranexamic acid
Description: 4 tablets of tranexamic acid 500mg (equal 2gm) 2 hours before surgery in the ward.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous tranexamic acid
Description: 15mg/kg of tranexamic acid in a 20ml syringe slowly intravenous during induction.
Study: NCT06438588

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary Intervention
Description: Given FMD

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational Intervention
Description: Receive educational guidelines

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electronic Health Record Review
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Interview
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nutritional Assessment
Description: Receive nutrition counseling

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT06216054

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LPM3770164 sustained release tablet
Description: administrated orally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: LPM3770164 sustained release tablet simulant
Description: administrated orally
Study: NCT06170541

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Aquilion Precision
Description: Ultra-High Resolution CT (UHR CT) capable of resolving anatomy as small as 150 microns, providing CT image quality with resolution typically seen only in cath labs. The UHR detector is newly designed to provide more than twice the resolution when compared with today's CT technology, with an all-new detector as well as tube, gantry and reconstruction technologies.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Computed Tomography
Description: Conventional reconstruction Computed Tomography (CT) represents a pivotal approach in medical imaging.
Study: NCT06370988

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: iTBS Stimulation
Description: Fluid-Cooled B70 A/P Coil with either Magventure X100 or R30

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham iTBS Stimulation
Description: Fluid-Cooled B70 A/P Coil with either Magventure X100 or R30
Study: NCT05592275

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3540378
Description: Administered SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3540378
Description: Administered SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3540378
Description: Administered SC

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered SC
Study: NCT04766684

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: J-Tip with Xylocaine MPF with placebo cream
Description: J-Tip with 0.25mL of 1% Xylocaine MPF with placebo cream

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: L.M.X.4 cream with J-Tip saline injection
Description: L.M.X.4 cream with J-Tip saline injection
Study: NCT06105632

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07220060 CDK4 inhibitor
Description: Experimental

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: Experimental and Active comparator

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fulvestrant
Description: Experimental and Active comparator

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Everolimus
Description: Active Comparator

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Exemestane
Description: Active Comparator
Study: NCT05232695

Intervention type: DIAGNOSTIC_TEST
Intervention: metabolically healthy obese
Description: Obese individuals will be divided into 2 groups as metabolic healthy and unhealthy obese, and their batokine concentrations will be compared.

Intervention type: DIAGNOSTIC_TEST
Intervention: metabolically healthy obese
Description: Obese individuals will be divided into 2 groups as metabolic healthy and unhealthy obese, and their batokine concentrations will be compared.
Study: NCT04278625

Intervention type: DRUG
Intervention: Acetaminophen
Description: IV acetaminophen given as part of standard of care.

Intervention type: DRUG
Intervention: Acetaminophen
Description: IV acetaminophen given as part of standard of care.
Study: NCT06059222

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Romosozumab
Description: Romosozumab 210 mg/2.34 ml from baseline to month 11

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zoledronate
Description: 5 mg/100 ml at month 12

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Romosozumab
Description: 210 mg/2.34 ml from baseline to month 5 and from month 18 to month 23

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zoledronate
Description: 5 mg/100 ml at month 6

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Romosozumab
Description: 210 mg/2.34 ml from baseline to month 5

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zoledronate
Description: 5 mg/100 ml at month 5 and month 18
Study: NCT05747196

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: WhiteSwell eLym System
Description: The WhiteSwell eLym™ System is designed to treat congestion in Acute Decompensated Heart Failure (ADHF) patients. The device comprises two endovascular components, a Catheter and a Sheath, that are used in combination with a Console. The device is designed to create a low-pressure zone at the Thoracic Duct Outflow which is located adjacent to the venous angle (junction of the left subclavian vein and left internal jugular vein). This low-pressure region facilitates movement of fluid (lymph) from the interstitial compartment through the lymphatic system and the Thoracic Duct and into the intravascular space, while removal of fluids from the intravascular space is enabled using diuretic therapy. The treatment duration will be up to 72 hours.
Study: NCT06075108

Intervention type: OTHER
Group type: OTHER
Intervention: P-KIDs CARE
Description: The P-KIDs CARE intervention will include two components: 1) the World Health Organization (WHO) Basic Emergency Care Course for training on patient assessment and stabilization, and 2) a decision support tool which integrates adaptation of two evidence-based tools: a) the Pediatric Resuscitation and Trauma Outcome model for mortality risk assessment, and 3) the Field Triage Decision Scheme to assist with timely referral decisions. WHO Basic Emergency Care Course includes modules delivered via PowerPoint with hands-on training components. The decision support tool will be online with checkboxes that healthcare providers can cross as they fill it out in real time. The team will adapt the tool for use in Northern Tanzania, with particular attention to local contextual and cultural factors.
Study: NCT06488378

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Axatilimab
Description: Humanized immunoglobulin G (IgG)4 monoclonal antibody, 1.3 mL sterile, preservative free glass vials, via intravenous (into the vein) infusion per protocol.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Inhibitor of poly ADP ribose polymerase (PARP)1-3, 100 or 150 mg tablet, taken orally per standard of care.
Study: NCT06467331

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hippotherapy
Description: Hippotherapy, also known as horse-assisted therapy, is a form of animal-assisted therapy. It consists of regularly scheduled sessions designed to enhance functionality in individuals' lives and contribute to their overall health improvement.
Study: NCT04914286

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GFH018
Description: Subjects are planned to be dosed in oral GFH018 tablets twice daily for a continuous 14 days in a 28 days cycle (7days on 7days off may be tested based on available data from phase I dose escalation study of single agent). the starting dose of GFH018 will be derived from the maximum safe dose explored in rom phase I dose escalation study of single agent.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab
Description: Subjects are planned to be dosed at 3 mg/kg Toripalimab as an intravenous infusion once every 2 weeks.
Study: NCT04468919

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BCI-FIT multi-modal access
Description: Adding a personalized multi-modal access protocol to customize a BCI-FIT access method configuration for each individual end user, based on a combination of user characteristics, clinical expertise, user feedback, and system performance data in the software.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BCI-FIT adaptive signal modeling
Description: Adding a BCI-FIT adaptive signal modeling that employs transfer learning and on-line model adaptation techniques with noisy labels in the software of this brain-computer interface to eliminate the need for data collection exclusively for model calibration, as well as to address model drift issues associated with drowsiness, fatigue, and other human and environmental factors.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BCI-FIT active querying
Description: Adding BCI-FIT active querying techniques which are software-based optimal action control policies in the brain-computer interface developed with active and reinforcement learning techniques in order to perform efficient user intent inference to improve the entire speed-accuracy trade-off curve for alternative communication.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BCI-FIT language modeling
Description: Adding vocabulary and location information (called partner and environmental input) to the language models in the brain-computer interface from a user's communication partner.
Study: NCT05611268

Intervention type: DRUG
Group type: OTHER
Intervention: Pentoxifylline
Description: Oral Pentoxifylline 400 mg/day for 30 days, followed by 800 mg/day for 150 days
Study: NCT06436924

Intervention type: DEVICE
Intervention: Left Atrial Appendage Device Implant
Description: The Watchman Device is implanted into the left atrial appendage and is designed to close it off and keep blood clots from escaping that area.
Study: NCT06320379

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Zypan
Description: The study product is a dietary supplement manufactured by Standard Process Inc (i.e., Zypan®). One serving (i.e., two tablets) contains a proprietary blend (595 mg) of the following: Betaine hydrochloride, bovine pancreas Cytosol™ extract, pepsin (1:10,000), pancreatin (3x), stearic acid (vegetable source), ammonium chloride, bovine spleen, and ovine spleen. Non active ingredients will include cellulose and calcium stearate. Participants will be instructed to take two tablets three times daily with meals

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator
Description: The control supplement will not contain any of the active ingredients in Zypan® and will also be manufactured by Standard Process Inc. Two tablets will contain 435 mg of cellulose (42%), 288 mg rice bran powder (28%), 201 mg of calcium lactate powder (19.5%\*), 103 mg citric acid (10%), and 2.6 mg calcium stearate (0.25%)